Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in the Netherlands / NCT07011368
Starting soon Not applicable

Empowering Healthy Lifestyle Personalised Intervention to Prevent and Control Obesity: The HealthyW8 Project

NCT07011368 · tracked via the Priya Life Science Netherlands tracker
Phase
Not applicable
Started
2025-07-01
Last updated
2025-07-01

Condition(s) studied

Obesity PreventionObesity and OverweightObesity and Obesity-related Medical ConditionsDigital HealthBehavioural Science Interventions to Improve Health Equity

Investigational drug(s) / intervention(s)

Intervention Group

Intervention Group: Healthy Lifestyle Recommender Solution (HLRS) will be developed as intervention tool for the trials. It integrates tools (mostly digital): a meal recommender to propose balanced and individually adapted meal plans, physical activity and sleep pattern measures and recommendations, assessment of behavioural/psychological aspects, and motivational features for sustained engagement and adherence. Within our multi-disciplinary portfolio approach, a set of predominantly eHealth solutions applied during the intervention trials for overweight/obesity prevention, developed in a participatory design approach with relevant stakeholders. This will include the HLRS, thus combining motivational features (nudging, gamification), targeted psychological support, dietary and physical activity advice, though also additional recommendations (healthy eating guidelines...) or education materials will be provided. Intervention trials/studies.

Study summary

The goal of the HealthyW8 study (an intervention study) is:

To assess the usefulness and effects of a digital-based healthy lifestyle recommender system (HRLS) on the prevention of obesity in the following propulations: schoolchildren (5-10 y) and their parents, young adults (18-25 y) and elders (\>65 y).

The main questions it aims to answer are:

Outcome 1: To select and validate a tool-assisted 3-mo intervention (mostly digital) by iteratively testing the HLRS on reducing risk of overweight/obesity among the described age groups.

Outcome 2: To assess the effect of 1-y interventions (mostly digital) with the HLRS described and further iteratively improved previously (outcome 1) on reducing risk of overweight/obesity at described ages.

Researchers will compare the intervention group before the intervention (baseline) and after it (3-mo intervention trial), or control group (standard care) vs. Intervention group (1-y intervention) to see changes on changes in overweight/obesity, and related parameters (body composition and biomarkers).

Participants will follow the HLRS recommendations (meal plans, physical activity and sleep pattern measures and recommendations, assessment of behavioural/psychological aspects, and motivational features through digital devices), which will be assessed by means of measurement of body weight, body composition, and biomarkers.

Eligibility

Sex
ALL
Min age
7 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Overweight (BMI between 25-30 kg/m\^2) * To have a smart phone Exclusion Criteria: * Individuals with manifest chronic diseases * Individuals with cognitive diseases * Individuas not able to lead an independent life

Primary outcome measure(s)

Trial sites (13)

FacilityCityRegionStatus
Virtech Ood Sofia Bulgaria
Regional Cluster North-East Varna Bulgaria
Danmarks Tekniske Universitet Kongens Lyngby Denmark
Leibniz-Institut Fur Praventionsforschung Und Epidemiologie - Bips Gmbh Bremen Germany
Deutsches Forschungszentrum Fur Kunstliche Intelligenz Gmbh Kaiserslautern Germany
Universita Degli Studi Di Scienze Gastronomiche Bra Italy
Luxembourg Institute of Health Luxembourg Luxembourg
Technische Universiteit Eindhoven Eindhoven Netherlands
Universidade de Coimbra Coimbra Portugal
Universidade de Evora Evora Portugal
Fundacio Institut D'Investigacio Sanitaria Illes Balears (Idisba) Palma de Mallorca Balearic Islands
Centre de Recerca En Economia I Desenvolupament Agroalimentari-Upc-Irta Castelldefels Spain
Centro de Investigacion Y Tecnologia Agroalimentaria de Aragon Zaragoza Spain

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07011368 on ClinicalTrials.gov ↗ ← All trials in the Netherlands